ASCO 2020

od Bartsch, Rupert, Dieras, Veronique, Cortes, Javier, Müller, Volkmar, Ruhstaller, Thomas
Izdano u Breast Care (Basel) (2020)

Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8–11, 2020

od Müller, Volkmar, Dieras, Veronique, Cardoso, Fatima, Cameron, David, Cortes, Javier
Izdano u Breast Care (Basel) (2021)

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic H...

od Paracha, Noman, Reyes, Adriana, Diéras, Véronique, Krop, Ian, Pivot, Xavier, Urruticoechea, Ander
Izdano u Breast Cancer Res Treat (2020)

Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib

od Zheng, Jenny, Yu, Yanke, Durairaj, Chandrasekar, Diéras, Véronique, Finn, Richard S., Wang, Diane D.
Izdano u Target Oncol (2020)

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall...

od Diéras, Véronique, Miles, David, Verma, Sunil, Pegram, Mark, Welslau, Manfred, Baselga, José, Krop, Ian E, Blackwell, Kim, Hoersch, Silke, Xu, Jin, Green, Marjorie, Gianni, Luca
Izdano u Lancet Oncol (2017)

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non‐metastatic breast cancer

od Bernadou, Guillemette, Campone, Mario, Merlin, Jean‐Louis, Gouilleux‐Gruart, Valérie, Bachelot, Thomas, Lokiec, François, Rezai, Keyvan, Arnedos, Monica, Diéras, Véronique, Jimenez, Marta, Paintaud, Gilles, Ternant, David
Izdano u Br J Clin Pharmacol (2016)

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

od Diéras, Véronique, Harbeck, Nadia, Joy, Anil Abraham, Gelmon, Karen, Ettl, Johannes, Verma, Sunil, Lu, Dongrui R., Gauthier, Eric, Schnell, Patrick, Mori, Ave, Rugo, Hope S., Finn, Richard S.
Izdano u Oncologist (2019)

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours

od Wilson, Richard H, Evans, TR Jeffry, Middleton, Mark R, Molife, L Rhoda, Spicer, James, Dieras, Veronique, Roxburgh, Patricia, Giordano, Heidi, Jaw-Tsai, Sarah, Goble, Sandra, Plummer, Ruth
Izdano u Br J Cancer (2017)

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated...

od Sabatier, Renaud, Diéras, Véronique, Pivot, Xavier, Brain, Etienne, Roché, Henri, Extra, Jean-Marc, Monneur, Audrey, Provansal, Magali, Tarpin, Carole, Bertucci, François, Viens, Patrice, Zemmour, Christophe, Gonçalves, Anthony
Izdano u Cancer Res Treat (2018)

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

od Tripathy, Debu, Tolaney, Sara M, Seidman, Andrew D, Anders, Carey K, Ibrahim, Nuhad, Rugo, Hope S, Twelves, Chris, Dieras, Veronique, Müller, Volkmar, Tagliaferri, Mary, Hannah, Alison L, Cortés, Javier
Izdano u Future Oncol (2019)

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

od Diéras, Véronique, Bachelot, Thomas, Campone, Mario, Isambert, Nicolas, Joly, Florence, Le Tourneau, Christophe, Cassier, Philippe, Bompas, Emmanuelle, Fumoleau, Pierre, Noal, Sabine, Orsini, Christine, Jimenez, Marta, Imbs, Diane Charlotte, Chatelut, Etienne
Izdano u Oncol Ther (2016)

Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

od Reyal, Fabien, Bollet, Marc A., Caly, Martial, Gentien, David, Carpentier, Sabrina, Peyro-Saint-Paul, Hélène, Pierga, Jean-Yves, Cottu, Paul, Dieras, Véronique, Sigal-Zafrani, Brigitte, Vincent-Salomon, Anne, Sastre-Garau, Xavier
Izdano 2012

Correction: Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

od Reyal, Fabien, Bollet, Marc A., Caly, Martial, Gentien, David, Carpentier, Sabrina, Peyro-Saint-Paul, Hélène, Pierga, Jean-Yves, Cottu, Paul, Dieras, Véronique, Sigal-Zafrani, Brigitte, Vincent-Salomon, Anne, Sastre-Garau, Xavier
Izdano 2012

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

od Verma, Sunil, Miles, David, Gianni, Luca, Krop, Ian E., Welslau, Manfred, Baselga, José, Pegram, Mark, Oh, Do-Youn, Diéras, Véronique, Guardino, Ellie, Fang, Liang, Lu, Michael W., Olsen, Steven, Blackwell, Kim
Izdano u N Engl J Med (2012)

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients

od Jobard, Elodie, Trédan, Olivier, Bachelot, Thomas, Vigneron, Arnaud M., Aït-Oukhatar, Céline Mahier, Arnedos, Monica, Rios, Maria, Bonneterre, Jacques, Diéras, Véronique, Jimenez, Marta, Merlin, Jean-Louis, Campone, Mario, Elena-Herrmann, Bénédicte
Izdano u Oncotarget (2017)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer

od Diéras, Véronique, Rugo, Hope S, Schnell, Patrick, Gelmon, Karen, Cristofanilli, Massimo, Loi, Sherene, Colleoni, Marco, Lu, Dongrui R, Mori, Ave, Gauthier, Eric, Huang Bartlett, Cynthia, Slamon, Dennis J, Turner, Nicholas C, Finn, Richard S
Izdano u J Natl Cancer Inst (2018)

Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breas...

od Finn, Richard S., Rugo, Hope S., Gelmon, Karen A., Cristofanilli, Massimo, Colleoni, Marco, Loi, Sherene, Schnell, Patrick, Lu, Dongrui R., Theall, Kathy Puyana, Mori, Ave, Gauthier, Eric, Bananis, Eustratios, Turner, Nicholas C., Diéras, Véronique
Izdano u Oncologist (2021)

MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer

od Dickler, Maura N., Tolaney, Sara M., Rugo, Hope S., Cortés, Javier, Diéras, Véronique, Patt, Debra, Wildiers, Hans, Hudis, Clifford A., O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Frenzel, Martin, Koustenis, Andrew, Baselga, José
Izdano u Clin Cancer Res (2017)

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers

od Hatem, Rana, Botty, Rania El, Chateau-Joubert, Sophie, Servely, Jean-Luc, Labiod, Dalila, de Plater, Ludmilla, Assayag, Franck, Coussy, Florence, Callens, Céline, Vacher, Sophie, Reyal, Fabien, Cosulich, Sabina, Diéras, Véronique, Bièche, Ivan, Marangoni, Elisabetta
Izdano u Oncotarget (2016)

NT-23 PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG)

od Kerklaan, Bojana Milojkovic, Jager, Agnes, Aftimos, Philippe, Dieras, Veronique, Altintas, Sevilay, Anders, Carey, Arnedos, Monica, Gelderblom, Hans, Soetekouw, Patricia, Gladdines, Werner, Gaillard, Pieter, de Sousa, Carlos, Awada, Ahmad, Schellens, Jan, van Linde, Myra, Brandsma, Dieta
Izdano 2014